...
首页> 外文期刊>Photodiagnosis and Photodynamic Therapy >Long-term follow-up and 'double layer sign' in patients affected by circumscribed choroidal hemangioma
【24h】

Long-term follow-up and 'double layer sign' in patients affected by circumscribed choroidal hemangioma

机译:受外脉络血管瘤影响的患者的长期随访和“双层标志”

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Photodynamic therapy has revolutionised the treatment of circumscribed choroidal hemangiomas. The aim of this report is to report the long-term follow-up of patients affected by circumscribed choroidal hemangioma treated using photodynamic therapy.Materials and Methods: We retrospectively reviewed patients affected by circumscribed choroidal hemangioma examined at the Retinal Medical Department at the Eye Clinic in Florence. We studied circumscribed choroidal hemangiomas treated using photodynamic therapy with at least 1 follow-up examination. Verteporfin was administered intravenously for 10 min (6 mg/m2 body surface area). After infusion (5 min), a 689 nm laser was applied with a light dose of 50 J/cm2.Results: Ten eyes of 10 patients with circumscribed choroidal hemangioma who underwent Photodynamic therapy were included in our series (2 females and 8 males; average age at diagnosis 47.8 +/- 9.3 yrs.; age range: 27-56 years). Five patients (5/10; 50 %) received only the photodynamic treatment whereas 5 patients (5/10; 50 %) also received other treatments (laser photocoagulation, intravitreal injection). On average, the patients received 2 photodynamic treatments (range 1-4). Four patients (4/10, 40 %) had a 5-year follow-up; (average 4.5 +/- 3.7 yrs. range 6 months - 10 years). In 2 patients we identified the "double layer sign" at the optical coherence tomography examination on circumscribed choroidal hemangioma.Conclusions: In our series, photodynamic therapy was a safe and effective treatment for circumscribed choroidal hemangioma during long-term follow-up. The double layer sign, which can be detected in several choroidal pathologies, suggests common pathogenetic mechanisms for circumscribed choroidal hemangiomas and central serous chorioretinopathy/polypoidal choroidopathy spectrum disease.
机译:背景:光动力疗法已彻底改变了对围绕脉络膜血管瘤的处理。本报告的目的是报告使用光动力疗法治疗的脉络膜血管瘤影响的长期随访。材料和方法:我们回顾性地审查了眼科视网膜医学部门在视网膜医学部门检查的受脉络膜血管瘤影响的患者在佛罗伦萨。我们研究了使用光动力疗法治疗的外接脉络膜血管瘤,至少有1例随访检查。静脉内施用至活翅10分钟(6mg / m 2体表面积)。输注后(5分钟),用50J / cm2的光剂量施用689nm激光剂:10名患者的10名患者接受光动力治疗的脉络膜血管瘤(2雌性)(2雌性和8名男性;诊断平均年龄47.8 +/- 9.3 YRS;年龄范围:27-56岁)。五名患者(5/10; 50%)仅接受光动力处理,而5例患者(5/10; 50%)也接受过其他治疗(激光光凝,玻璃体内注射)。平均而言,患者接受了2个光动力学处理(范围1-4)。四名患者(4/10,40%)有一个> 5年的随访; (平均4.5 +/- 3.7 YRS。范围为6个月 - 10年)。在2名患者中,我们在外接脉络膜血管瘤上鉴定了光学相干断层扫描检查的“双层标志”。结论:在我们的系列中,光动力治疗是在长期随访期间对外接脉络膜血管瘤的安全有效治疗。可以在几种脉络膜病理中检测的双层标志表明了常规的脉络膜血管瘤和中枢浆液性胆管病皮病/息肉脉络膜病谱疾病的常见致病机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号